XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Jul. 07, 2022
Aug. 01, 2021
Jun. 08, 2017
Jul. 16, 2021
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies (Details) [Line Items]                
License fees     $ 7,529          
Payment to licensor         $ 45,000      
Fee payment       $ 12,700,000        
Milestone payment       $ 160,000,000        
Rent amount   $ 11,000     $ 14,500     $ 9,000
Lease period         5 months      
Lease agreement expiry date         Dec. 31, 2023      
Lease expense         $ 213,500 $ 87,100    
Assets         493,452      
Lease payments receivable         $ 397,049      
Discount rate         8.38%      
Loss on sales-type lease of fixed assets         $ 96,403      
Minimum [Member]                
Commitments and Contingencies (Details) [Line Items]                
License agreement term         15 years      
Maximum [Member]                
Commitments and Contingencies (Details) [Line Items]                
License agreement term         20 years      
Forecast [Member]                
Commitments and Contingencies (Details) [Line Items]                
Rent amount             $ 7,000  
License Agreements [Member]                
Commitments and Contingencies (Details) [Line Items]                
Description of rights granted to license agreement         In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.      
FFE [Member]                
Commitments and Contingencies (Details) [Line Items]                
Purchase amount $ 52,698              
Leases and Sublease [Member]                
Commitments and Contingencies (Details) [Line Items]                
Lease agreement expiry date         Dec. 31, 2021      
Wonpung [Member]                
Commitments and Contingencies (Details) [Line Items]                
License fees         $ 1,500,000      
Net sales rate         12.00%      
Third Party Licensor [Member] | Business Combination [Member] | License Agreements [Member]                
Commitments and Contingencies (Details) [Line Items]                
Business acquisition, description         Based upon a prior acquisition, the Company assumed an obligation to pay third parties (Dr. Charles E. Inturrisi and Dr. Paolo Manfredi – see below): (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of September 30, 2023, the Company has not generated any revenue related to this license agreement.